Nephro Care India Ltd
₹ 129
-4.04%
04 Nov
- close price
About
Incorporated in 2014, Nephro Care India Ltd is a healthcare provider that specializes
in the treatment of kidney- related diseases[1]
Key Points
- Market Cap ₹ 213 Cr.
- Current Price ₹ 129
- High / Low ₹ 256 / 100.0
- Stock P/E 74.4
- Book Value ₹ 32.4
- Dividend Yield 0.00 %
- ROCE 11.3 %
- ROE 8.38 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Upcoming result date: 12 November 2025
Profit & Loss
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 0.54 | 1.82 | 3.42 | 17.09 | 27.23 | 46.03 | |
| 0.52 | 1.67 | 3.28 | 13.66 | 20.76 | 40.16 | |
| Operating Profit | 0.02 | 0.15 | 0.14 | 3.43 | 6.47 | 5.87 |
| OPM % | 3.70% | 8.24% | 4.09% | 20.07% | 23.76% | 12.75% |
| 0.01 | 0.01 | -0.01 | 0.00 | 0.28 | 1.53 | |
| Interest | 0.04 | 0.03 | 0.02 | 0.07 | 0.09 | 0.11 |
| Depreciation | 0.00 | 0.01 | 0.11 | 0.78 | 0.53 | 2.46 |
| Profit before tax | -0.01 | 0.12 | 0.00 | 2.58 | 6.13 | 4.83 |
| Tax % | 0.00% | 25.00% | 7.75% | 28.06% | 24.64% | |
| -0.01 | 0.09 | -0.01 | 2.37 | 4.41 | 3.64 | |
| EPS in Rs | -10.00 | 90.00 | -0.20 | 47.40 | 3.71 | 2.21 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 143% |
| 3 Years: | 138% |
| TTM: | 69% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 211% |
| 3 Years: | 109% |
| TTM: | -33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -49% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 21% |
| Last Year: | 8% |
Balance Sheet
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.50 | 0.50 | 11.90 | 16.49 |
| Reserves | 0.07 | 0.01 | 0.00 | 2.03 | 3.12 | 37.00 |
| 0.40 | 0.69 | 2.54 | 2.48 | 0.00 | 0.00 | |
| 0.30 | 0.42 | 1.60 | 3.25 | 5.94 | 14.79 | |
| Total Liabilities | 0.78 | 1.13 | 4.64 | 8.26 | 20.96 | 68.28 |
| 0.45 | 0.06 | 1.39 | 3.01 | 4.74 | 31.48 | |
| CWIP | 0.00 | 0.45 | 1.90 | 0.00 | 0.86 | 0.61 |
| Investments | 0.24 | 0.00 | 0.00 | 2.00 | 6.51 | 18.58 |
| 0.09 | 0.62 | 1.35 | 3.25 | 8.85 | 17.61 | |
| Total Assets | 0.78 | 1.13 | 4.64 | 8.26 | 20.96 | 68.28 |
Cash Flows
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 0.23 | 0.62 | 4.12 | 0.91 | 7.82 | ||
| -0.06 | -2.81 | -2.33 | -7.54 | -39.56 | ||
| 0.28 | 2.32 | -0.08 | 5.60 | 35.10 | ||
| Net Cash Flow | 0.44 | 0.13 | 1.71 | -1.03 | 3.37 |
Ratios
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 20.28 | 0.85 | 2.01 | 25.61 |
| Inventory Days | 8.83 | 41.93 | 35.25 | 14.07 | 34.38 | |
| Days Payable | 94.19 | 113.45 | 69.03 | 75.17 | 107.32 | |
| Cash Conversion Cycle | 0.00 | -85.36 | -51.24 | -32.93 | -59.09 | -47.33 |
| Working Capital Days | -168.98 | -88.24 | -124.87 | -56.81 | -36.86 | -51.23 |
| ROCE % | 25.21% | 1.60% | 65.84% | 60.41% | 11.27% |
Documents
Announcements
-
Structural Digital Database
17 October 2025 - SDD compliance certificate for quarter ended Sept 30, 2025; one event captured; no non-compliances.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
7 October 2025 - Reg 74(5) certificate for quarter ended 30 Sep 2025; no rematerialisation requests.
-
General Updates
4 October 2025 - Promoter Dr. Pratim Sengupta received Times Network healthcare excellence appreciation on 4 October 2025.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
4 October 2025 - Listed on NSE EMERGE July 05, 2024; Corporate governance regs (Reg 27(2)) not applicable.
-
Trading Window
22 September 2025 - Trading window closed Oct 1, 2025 until 48 hours after unaudited H1 results for period ended Sep 30, 2025.
Annual reports
Concalls
-
Aug 2025TranscriptNotesPPT
Business Overview:[1][2]
NCIL provides comprehensive medical services for renal patients as a one-stop treatment center in Kolkata. It offers clinical and lifestyle solutions for renal insufficiency, covering lifestyle, physiological, and spiritual wellness. The company specializes in non-invasive services.